Ultragenyx Pharmaceutical Inc.(RARE) Stock Research - Grey Stern Research

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis

$35.61 (2.21%)

RARE Financial Performance


Use the table below to view Ultragenyx Pharmaceutical Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $35.61 -
52 Week Low $29.59 -
52 Week High $60.37 -
Market Cap $3.4 Billion 6/16
Gross Margin 90% 5/16
Profit Margin -81% 13/16
EBITDA margin -66% 6/16
Q4 - 2024 Revenue $164.9 Million 5/16
Q4 - 2024 Earnings -$133.4 Million 14/16
Q4 - 2024 Free Cash Flow -$80.2 Million 12/16
Trailing 4 Quarters Revenue $560.2 Million 5/16
Trailing 4 Quarters Earnings -$569.2 Million 13/16
Quarterly Earnings Growth -8% 11/16
Annual Earnings Growth 5% 7/16
Quarterly Revenue Growth 29% 7/16
Annual Revenue Growth 33% 6/16
Cash On Hand $173.7 Million 9/16
Short Term Debt $10.3 Million 6/16
Long Term Debt $30.0 Million 9/16

Ultragenyx Pharmaceutical Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Ultragenyx Pharmaceutical Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/16
PS 6.01 7/16
PB 12.84 2/16
PC 19.38 2/16
Liabilities to Equity 4.86 3/16
ROA -0.38 12/16
ROE -2.23 14/16
Current Ratio 1.21 14/16
Quick Ratio 0.49 16/16
Long Term Debt to Equity 0.12 7/16
Debt to Equity 0.16 6/16
Burn Rate 1.27 12/16
Cash to Cap 0.05 15/16
CCR 0.60 13/16
EV to EBITDA -29.72 14/16
EV to Revenue 5.77 6/16

Company Details

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

CEO: Dr. Emil Kakkis

Website: https://www.ultragenyx.com

Address: 60 Leveroni Ct Novato, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Ultragenyx Pharmaceutical Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Ultragenyx Pharmaceutical Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $37.2 Billion
Incyte Corporation INCY $12.3 Billion
Kura Oncology, Inc. KURA $521.2 Million
Mirati Therapeutics, Inc. MRTX $4.1 Billion
United Therapeutics Corporation UTHR $13.8 Billion
Apellis Pharmaceuticals, Inc. APLS $2.2 Billion
Arvinas, Inc. ARVN $473.7 Million
Crinetics Pharmaceuticals, Inc. CRNX $2.9 Billion
PDS Biotechnology Corporation PDSB $64.9 Million
X4 Pharmaceuticals, Inc. XFOR $16.9 Million
Revolution Medicines, Inc. RVMD $7.4 Billion
Inozyme Pharma, Inc. INZY $255.0 Million
Terns Pharmaceuticals, Inc. TERN $251.5 Million
Day One Biopharmaceuticals, Inc. DAWN $633.5 Million
Acumen Pharmaceuticals, Inc. ABOS $64.8 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RARE Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 164.9 Million -$133.4 Million
Q3 2024 $ 139.5 Million -$133.5 Million
Q2 2024 $ 147.0 Million -$131.6 Million
Q1 2024 $ 108.8 Million -$170.7 Million
Q4 2023 $ 127.4 Million -$123.2 Million
Q3 2023 $ 98.1 Million -$159.6 Million
Q2 2023 $ 108.3 Million -$159.8 Million
Q1 2023 $ 100.5 Million -$164.0 Million

View All

RARE Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $173.7 Million $1.5 Billion $40.3 Million $262.3 Million
Q3 2024 $150.6 Million $1.5 Billion $10.4 Million $353.8 Million
Q2 2024 $486.9 Million $1.6 Billion $926.5 Million $432.4 Million
Q1 2024 $118.6 Million $1.3 Billion $932.2 Million $140.3 Million
Q4 2023 $213.6 Million $1.5 Billion $43.2 Million $275.4 Million
Q3 2023 $72.6 Million $1.2 Billion $12.1 Million $31.7 Million
Q2 2023 $102.1 Million $1.3 Billion $25.7 Million $129.0 Million
Q1 2023 $85.8 Million $1.4 Billion $28.6 Million $220.5 Million

View All

RARE Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 -$80.2 Million -$654,000 $23.9 Million
Q3 2024 -$56.1 Million $10.9 Million -$326.7 Million
Q2 2024 -$81.5 Million -$4.5 Million $368.3 Million
Q1 2024 -$203.9 Million -$13.2 Million -$97.0 Million
Q4 2023 -$85.5 Million -$1.6 Million $144.8 Million
Q3 2023 $34.9 Million $0 $34.9 Million
Q2 2023 -$132.6 Million -$16.4 Million $16.1 Million
Q1 2023 -$181.9 Million -$25.0 Million -$46.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions